- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Clinical, Journal: Bolus administration of remimazolam was superior to midazolam for deep sedation in elderly patients undergoing diagnostic bronchoscopy: A randomized, double-blind, controlled trial. (Pubmed Central) - Mar 26, 2024
Bolus administration of remimazolam offers advantages over midazolam for deep sedation in elderly patients undergoing DFB, in terms of a higher success rate of sedation and a lower incidence of extra sleep within 6 hours after procedure, though the safety profiles of both groups were favorable.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal: The Metabolism of the New Benzodiazepine Remimazolam. (Pubmed Central) - Mar 25, 2024
However, further studies are required to confirm these findings. Besides the pharmacologically non-active metabolite CNS7054, no other clinically significant metabolite of remimazolam could be identified.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma, dexmedetomidine / Generic mfg.
Journal: Anti-inflammatory potential of remimazolam: A laboratory and clinical investigation. (Pubmed Central) - Mar 18, 2024
No abstract available Remimazolam exerted stronger anti-inflammatory effects than dexmedetomidine, and these effects were enhanced by its antioxidant properties, which may have affected postoperative CRP production.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal: The effect of remimazolam on hypotension risk during procedural sedation. (Pubmed Central) - Mar 18, 2024
Remimazolam exerted stronger anti-inflammatory effects than dexmedetomidine, and these effects were enhanced by its antioxidant properties, which may have affected postoperative CRP production. No abstract available
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Clinical, Surgery: Clinical Study of Flumazenil Antagonizing Remimazolam on Nausea and Vomiting After Gynecologic Day Surgery. (Pubmed Central) - Mar 15, 2024
Dexamethasone 5 mg, flurbiprofen axetil 50 mg, and droperidol 1 mg were given intravenously before induction of anesthesia in both groups...After the patient fell asleep, mivacurium chloride 0.2mg / kg was injected for 30 seconds and alfentanil 20ug / kg was injected for 30 seconds...The incidence of PONV in the PACU was 5.6% in group F and 8.6% in group C. The difference was not statistically significant (p > 0.05). Flumazenil antagonism of remimazolam increases the incidence of PONV within 24 hours in gynecologic day surgery patients and has no significant effect on the incidence of PONV in the PACU.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
COMPARISON BETWEEN REMIMAZOLAM AND PLACEBO IN JAPANESE PATIENTS UNDERGOING COLONOSCOPY: A PHASE III, INVESTIGATOR-INITIATED, RANDOMIZED, CONTROLLED TRIAL (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7774;
In addition, adequate sedation was achieved for Japanese patients at lower doses than reported in Western countries. The findings of this study indicate that remimazolam may be an acceptable sedative for colonoscopic procedures.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Enrollment open: Sedative Effect and Safety of Remimazolam Besylate in ARDS Patients (clinicaltrials.gov) - Mar 13, 2024
P4, N=100, Recruiting,
Therefore, this new drug should be further studied and more research with larger population sizes should be carried out to confirm this hypothesis. Not yet recruiting --> Recruiting
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Enrollment open, Trial completion date, Trial primary completion date: ED90 of Remimazolam Anesthesia Induction in Painless Bidirectional Endoscopy in Children (clinicaltrials.gov) - Mar 13, 2024
P4, N=165, Recruiting,
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Trial completion, Surgery: Effect of Remimazolam on the Recovery Quality After Day Surgery (clinicaltrials.gov) - Mar 12, 2024
P=N/A, N=118, Completed,
Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024 Recruiting --> Completed
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Trial primary completion date, Surgery: Effect of Remimazolam and Propofol on Postoperative Delirium (clinicaltrials.gov) - Mar 12, 2024
P=N/A, N=82, Recruiting,
Recruiting --> Completed Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal: The effective dose of remimazolam in adult gastroscopy. (Pubmed Central) - Mar 12, 2024
The ED50 and ED95 of remimazolam for adult gastroscopy were 0.362 mg/kg and 0.464 mg/kg, respectively. Additional anesthetics might be required during gastroscopy in some patients.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Retrospective data, Journal: Efficacy and safety of remimazolam in bronchoscopic sedation: A meta-analysis. (Pubmed Central) - Mar 11, 2024
The sedation success rate was similar to that in the CS group. However, remimazolam has a higher safety profile, with fewer inhibitory effects on respiration and circulation.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Enrollment open: Esketamine vs Remimazolam for Postoperative Sleep Disturbance and Anxiety (clinicaltrials.gov) - Mar 5, 2024
P=N/A, N=300, Recruiting,
In this patient with HOCM, remimazolam and remifentanil provided adequate anesthesia for induction and maintenance to complete the right hemicolectomy. Not yet recruiting --> Recruiting
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Retrospective data, Journal: Remimazolam: A Retrospective Study of Initial Safety and Recovery Data in Diverse Procedural Sedation. (Pubmed Central) - Feb 27, 2024
For women undergoing hysteroscopic procedures, remimazolam at doses from 0.1 to 0.2 mg Remimazolam presents as a promising option for nurse procedural sedation, offering minimal impact on hemodynamics and respirations, quick recovery, and no residual sedative effects.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal: Effective remimazolam loading dose for adequate sedation in regional anesthesia. (Pubmed Central) - Feb 21, 2024
P4
In conclusion, remimazolam could be considered an effective anesthetic drug for patients with SPS. The ED90 of the remimazolam loading dose to achieve adequate sedation in patients undergoing limb surgery under regional anesthesia was 0.617
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Review, Journal: Benefits of remimazolam as an anesthetic sedative for older patients: A review. (Pubmed Central) - Feb 19, 2024
This article elaborates on the benefits of remimazolam compared with those of other anesthetic sedatives for sedation in older patients to demonstrate how it offers a new option for anesthetics in older patients. In cases involving older patients with increased clinical complexities or very old patients requiring anesthesia, remimazolam can be selected as the preferred anesthetic sedative, as outlined in this review.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal: Remimazolam attenuates inflammation and kidney fibrosis following folic acid injury. (Pubmed Central) - Feb 19, 2024
Additionally, the benzodiazepine receptor antagonist PK-11195 partially reversed the protective effect of remimazolam on the FA-injured kidneys. Overall, remimazolam attenuates the inflammatory response and renal fibrosis development following FA-induced AKI, which may be related to the peripheral benzodiazepine receptor pathway.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Trial completion date, Trial primary completion date: Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients (clinicaltrials.gov) - Feb 15, 2024
P2, N=36, Completed,
Overall, remimazolam attenuates the inflammatory response and renal fibrosis development following FA-induced AKI, which may be related to the peripheral benzodiazepine receptor pathway. Trial completion date: Jun 2023 --> Feb 2023 | Trial primary completion date: Jun 2023 --> Feb 2023
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
New trial: Remimazolam in High Risk ERCP Patients (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=60, Not yet recruiting,
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal, Head-to-Head: Remimazolam dosing for gastroscopy: a randomized noninferiority trial. (Pubmed Central) - Feb 14, 2024
Trial completion date: Jun 2023 --> Feb 2023 | Trial primary completion date: Jun 2023 --> Feb 2023 This trial established the noninferior sedation success rate of remimazolam (0.2?mg/kg but not 0.15?mg/kg) compared with propofol (1.5?mg/kg), with a superior safety profile.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Trial completion, Trial primary completion date: Comparison of Remimazolam and Midazolam for Preventing Intraoperative Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia (clinicaltrials.gov) - Feb 6, 2024
P=N/A, N=80, Completed,
Therefore, while using remimazolam alongside remifentanil infusion without NMBAs for ISA insertion, one should consider the patient's sex for appropriate dosing. Recruiting --> Completed | Trial primary completion date: Nov 2023 --> May 2023
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal, Surgery: Efficacy of Single-Bolus Administration of Remimazolam During Induction of Anesthesia in Patients Undergoing Cardiac Surgery: A Prospective, Single-Center, Randomized Controlled Study. (Pubmed Central) - Feb 5, 2024
A 0.2 mg/kg bolus injection of remimazolam resulted in the shortest time to loss of responsiveness among the 3 groups, without significantly altering the hemodynamic parameters. Therefore, this dosing can be considered a favorable anesthetic induction method for patients undergoing cardiac surgery.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Clinical, Surgery: Comparison of Remimazolam versus Sevoflurane on the Postoperative Quality of Recovery in Cervical Spine Surgery: A Prospective Randomized Controlled Double-Blind Trial. (Pubmed Central) - Feb 2, 2024
Instead, patients in group R showed significantly better sub-scores in psychological and postoperative nausea and vomiting (PONV) items on POD1, as well as a lower degree of PONV, than those in group S. Among the five dimensions of the QoR-15, a significant group-time interaction effect was observed for psychological support. Group R showed significantly less changeability in blood pressure and heart rate with a lower dose of intraoperatively administered vasopressor than group S. Considering QoR-15, including PONV reduction, and intraoperative hemodynamic stability, remimazolam can be used as the novel and safe anesthetic agent for maintaining general anesthesia instead of sevoflurane in patients undergoing ACDF.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Journal, Surgery: Comparison of recovery profiles between total intravenous anaesthesia with propofol or remimazolam reversed with flumazenil in patients undergoing breast surgery: A randomised controlled trial. (Pubmed Central) - Feb 2, 2024
P=N/A
Group R showed significantly less changeability in blood pressure and heart rate with a lower dose of intraoperatively administered vasopressor than group S. Considering QoR-15, including PONV reduction, and intraoperative hemodynamic stability, remimazolam can be used as the novel and safe anesthetic agent for maintaining general anesthesia instead of sevoflurane in patients undergoing ACDF. Administration of remimazolam with flumazenil may be a promising option for patients undergoing breast cancer surgery, providing faster recovery and better SAS scores than propofol during emergence from general anaesthesia.
- |||||||||| ByFavo (remimazolam) / PAION, Cosmo Pharma, Mundipharma, Pharmascience, Eagle Pharma
Trial completion, Trial completion date, Trial primary completion date: ShoSReB: Step 2 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients (clinicaltrials.gov) - Jan 31, 2024
P3, N=164, Completed,
Registered on 7 December 2022. Recruiting --> Completed | Trial completion date: May 2025 --> Nov 2023 | Trial primary completion date: Dec 2024 --> Nov 2023
|
